West Pharmaceutical Services, Inc. (WST)
Automate Your Wheel Strategy on WST
With Tiblio's Option Bot, you can configure your own wheel strategy including WST - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol WST
- Rev/Share 40.9433
- Book/Share 40.5131
- PB 6.2096
- Debt/Equity 0.1035
- CurrentRatio 2.7802
- ROIC 0.1388
- MktCap 18089719461.0
- FreeCF/Share 4.758
- PFCF 52.5864
- PE 37.2945
- Debt/Assets 0.0767
- DivYield 0.0033
- ROE 0.1766
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | WST | Barclays | -- | Equal Weight | -- | $245 | June 24, 2025 |
| Initiation | WST | Evercore ISI | -- | Outperform | -- | $275 | March 18, 2025 |
| Upgrade | WST | Deutsche Bank | Hold | Buy | -- | $250 | Feb. 14, 2025 |
| Initiation | WST | Citigroup | -- | Buy | -- | $400 | Jan. 8, 2025 |
| Initiation | WST | Wolfe Research | -- | Peer Perform | -- | -- | Dec. 13, 2024 |
| Upgrade | WST | UBS | Neutral | Buy | $350 | $390 | Dec. 12, 2024 |
News
West Pharmaceutical Services, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - WST
Published: May 01, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations.
Read More
Lost Money on West Pharmaceutical Services, Inc. (WST)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
Published: April 30, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations.
Read More
Did West Pharmaceutical Services, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - WST
Published: April 29, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations.
Read More
WST Stock Rises on Q1 Earnings Beat, EPS View Up on Tariff & FX Benefit
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Positive
West Pharmaceutical's first-quarter top line continues to benefit from revenue growth in its Proprietary Products segment.
Read More
WST ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by West Pharmaceutical Services, Inc.
Published: April 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations.
Read More
West Pharmaceutical Services, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - WST
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations.
Read More
West Pharmaceutical Services, Inc. (WST) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations.
Read More
West Announces Second-Quarter Dividend
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral
EXTON, Pa. , Feb. 20, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a second-quarter 2025 dividend of $0.21 per share. The dividend will be paid on May 7, 2025, to shareholders of record as of April 30, 2025.
Read More
West Pharmaceuticals Takes A Plunge, But May Still Offer Opportunities
Published: February 17, 2025 by: Seeking Alpha
Sentiment: Positive
The price of West Pharmaceutical Services plunged over 38% after it released its Q4 and FY 2024 earnings results on February 13. Shareholders, mostly institutional investors apparently, did not like the bottom-line results nor the uninspiring guidance for 2025. Still, West should not be overlooked, and there may be opportunities if the share price continues to rebound after a market overreaction.
Read More
Is WST Stock Undervalued At $200?
Published: February 14, 2025 by: Forbes
Sentiment: Positive
West Pharmaceutical Services, a global provider of solutions for drugs, biologics, gene therapies, and consumer healthcare products, recently announced its Q4 results, surpassing analysts' expectations for both revenue and earnings. The company reported sales of $749 million and adjusted earnings per share of $1.82, compared to $740 million and $1.73, respectively.
Read More
West Pharmaceutical Services, Inc. (WST) Q4 2024 Earnings Call Transcript
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Neutral
West Pharmaceutical Services, Inc. (NYSE:WST ) Q4 2024 Earnings Conference Call February 13, 2025 9:00 AM ET Company Participants John Sweeney - Vice President of Investor Relations Eric Green - Chairman, President & Chief Executive Officer Bernard Birkett - Senior Vice President & Chief Financial Officer Conference Call Participants Michael Ryskin - BofA Global Research Lawrence Solow - CJS Securities Patrick Donnelly - Citigroup Inc. Paul Knight - KeyBanc Capital Markets Matthew Larew - William Blair & Company Justin Bowers - Deutsche Bank David Windley - Jefferies Jacob Johnson - Stephens Inc. Operator Thank you for standing by and welcome …
Read More
West Pharma's stock tanks 33% to lead S&P 500 decliners as guidance misses by a wide margin
Published: February 13, 2025 by: Market Watch
Sentiment: Negative
West Pharmaceutical Services Inc.'s stock tumbled 33% Thursday, to lead S&P 500 decliners, after the manufacturer of injectable-pharmaceutical packaging and delivery systems offered guidance for 2025 that was well below expectations.
Read More
West Announces Fourth-Quarter and Full-Year 2024 Results
Published: February 13, 2025 by: PRNewsWire
Sentiment: Neutral
- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa.
Read More
Will Segmental Performance Drive West Pharmaceutical's Q4 Earnings?
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
West Pharmaceutical Services WST is scheduled to release fourth-quarter 2024 results on Feb. 13, before the opening bell. In the last reported quarter, the company delivered an earnings beat of 22.52%.
Read More
About West Pharmaceutical Services, Inc. (WST)
- IPO Date 1980-03-17
- Website https://www.westpharma.com
- Industry Medical - Instruments & Supplies
- CEO Eric M. Green
- Employees 10600